Zhao Yi, Luan Xiaofei, Wang Yuya
Women's Hospital, School of Medcine, Zhejiang University, Hangzhou, China.
Hainan General Hospital, Haikou, China.
Gynecol Endocrinol. 2021 Jan;37(1):51-55. doi: 10.1080/09513590.2020.1807502. Epub 2020 Sep 16.
To compare the efficacy and the tolerability of letrozole combined with oral contraceptives versus oral contraceptives alone in treating endometriosis-related pain.
A total of 820 women with endometriosis presented with endometriosis-related pain were enrolled with this study. Patients were randomly treated either with letrozole (2.5 mg/day) combined with oral contraceptives ( or oral contraceptives () alone for 6 months. Changes in pain symptoms during treatment and in 1 months after treatment, 6-month follow-up and 12-month follow-up were evaluated. Adverse effects of each treatment protocol were recorded.
At completion of treatment, the intensity of chronic pelvic pain continued to decrease during treatment and at 1-month after treatment it was significantly lower than at 6-month follow-up and baseline level both in LE + oral contraceptives group (Mean ± SD,1.5 ± 1.4) and in oral contraceptives alone group(Mean ± SD,2.9 ± 1.2).The intensity of chronic pelvic pain and deep dyspareunia was significantly decrease at both 1-month after treatment and 6-month follow-up.
This treatment for endometriosis is a promising new modality that warrants further investigation.
比较来曲唑联合口服避孕药与单纯口服避孕药治疗子宫内膜异位症相关疼痛的疗效和耐受性。
本研究共纳入820例患有子宫内膜异位症相关疼痛的女性。患者被随机分为接受来曲唑（2.5毫克/天）联合口服避孕药治疗（或单纯口服避孕药治疗），为期6个月。评估治疗期间、治疗后1个月、6个月随访和12个月随访时疼痛症状的变化。记录每种治疗方案的不良反应。
治疗结束时，慢性盆腔疼痛强度在治疗期间持续下降，治疗后1个月，来曲唑联合口服避孕药组（均值±标准差，1.5±1.4）和单纯口服避孕药组（均值±标准差，2.9±1.2）的疼痛强度均显著低于6个月随访时和基线水平。治疗后1个月和6个月随访时，慢性盆腔疼痛和深部性交困难的强度均显著降低。
这种子宫内膜异位症治疗方法是一种有前景的新方式，值得进一步研究。
